Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil

Journal of the American Heart Association

Volumn 4, Issue 4, 2015, Pages

  Vicente, Jose ^a,b,c   Johannesen, Lars ^a,d   Mason, Jay W ^f   Crumb, William J ^g   Pueyo, Esther ^a,c,e   Stockbridge, Norman ^b   Strauss, David G ^a,d  

^a Office of Science and Engineering Laboratories   (United States)

^b CDER   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^f Spaulding Clinical Research ^*  (United States)

^g ZENAS TECHNOLOGIES LLC   (United States)

Author keywords

Electrocardiography; Ion channels; Long QT syndrome; Pharmacology; Torsade de pointes

Indexed keywords

CALCIUM; CALCIUM CHANNEL L TYPE; DOFETILIDE; PLACEBO; POTASSIUM CHANNEL HERG; QUINIDINE SULFATE; RANOLAZINE; SODIUM; VERAPAMIL; CALCIUM CHANNEL BLOCKING AGENT; KCNH2 PROTEIN, HUMAN; PHENETHYLAMINE DERIVATIVE; QUINIDINE; SODIUM CHANNEL BLOCKING AGENT; SULFONAMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG MECHANISM; ELECTROCARDIOGRAPHY; EXPERIMENTAL STUDY; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PATCH CLAMP TECHNIQUE; PHASE 1 CLINICAL TRIAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SODIUM CURRENT; T WAVE; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; HEART; LONG QT SYNDROME;

ADULT; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; ELECTROCARDIOGRAPHY; ERG1 POTASSIUM CHANNEL; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HEART; HUMANS; LONG QT SYNDROME; MALE; PHENETHYLAMINES; QUINIDINE; RANOLAZINE; SODIUM CHANNEL BLOCKERS; SULFONAMIDES; VERAPAMIL;

EID: 85012249416     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.001615     Document Type: Article

References (40)

1. Antzelevitch C, Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol. 2002;17:43-51.
2. Sauer AJ, Newton-Cheh C. Clinical and genetic determinants of torsade de pointes risk. Circulation. 2012;125:1684-1694.
3. Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL, Schwartz PJ, Towbin JA, Vincent GM, Lehmann MH. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation. 1995;92:2929- 2934.
4. Stockbridge N, Morganroth J, Shah R, Garnett C. Dealing with global safety issues: was the response to QT-liability of non-cardiac drugs well coordinated Drug Saf. 2013;36:167-182.
5. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PKS, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TGB. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58:32-45.
6. US Food and Drug Administration. Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. 2005. Available at: http://www.fda.gov/downloads/ drugs/guidancecomplianceregulatoryinformation/guidances/ucm0731 53.pdf. Accessed March 26, 2015.
7. International Conference on Harmonisation. ICH Topic S7B The nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. 2005. Available at: http:// www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/ S7B/Step4/S7B_Guideline.pdf. Accessed March 26, 2015.
8. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med. 1994;121:529-535.
9. Aiba T, Shimizu W, Inagaki M, Noda T, Miyoshi S, Ding WG, Zankov DP, Toyoda F, Matsuura H, Horie M, Sunagawa K. Cellular and ionic mechanism for druginduced long QT syndrome and effectiveness of verapamil. J Am Coll Cardiol. 2005;45:300-307.
10. Antzelevitch C. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm. 2005;2:S9-S15.
11. January CT, Riddle JM. Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current. Circ Res. 1989;64:977-990.
12. Kramer J, Obejero-Paz CA, Myatt G, Kuryshev YA, Bruening-Wright A, Verducci JS, Brown AM. MICE models: superior to the HERG model in predicting Torsade de Pointes. Sci Rep. 2013;3:2100.
13. Roden D, Woosley R, Primm R. Incidence and clinical features of the quinidineassociated long QT syndrome: implications for patient care. Am Heart J. 1986;111:1088-1093.
14. Wu L, Guo D, Li H, Hackett J, Yan GX, Jiao Z, Antzelevitch C, Shryock JC, Belardinelli L. Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine. Heart Rhythm. 2008;5:1726-1734.
15. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Thomas G. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904-910.
16. Johannesen L, Vicente J, Mason JW, Sanabria C, Waite-Labott K, Hong M, Guo P, Lin J, Sorensen JS, Galeotti L, Florian J, Ugander M, Stockbridge N, Strauss DG. Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil. Clin Pharmacol Ther. 2014;96:549-558.
17. Andersen MP, Xue J, Graff C, Hardahl TB, Toft E, Kanters JK, Christiansen M, Jensen HK, Struijk JJ. A robust method for quantification of IKr-related T-wave morphology abnormalities. Comput Cardiol. 2007;34:341-344.
18. Couderc JP, Vaglio M, Xia X, McNitt S, Hyrien O. Electrocardiographic method for identifying drug-induced repolarization abnormalities associated with a reduction of the rapidly activating delayed rectifier potassium current. Conf Proc IEEE Eng Med Biol Soc. 2006;1:4010-4015.
19. Couderc JP, McNitt S, Hyrien O, Vaglio M, Xia X, Polonsky S, Moss A, Zareba W. Improving the detection of subtle I(Kr)-inhibition: assessing electrocardiographic abnormalities of repolarization induced by moxifloxacin. Drug Saf. 2008;31:249-260.
20. Kardys I, Kors JA, van der Meer IM, Hofman A, van der Kuip DA, Witteman JC. Spatial QRS-T angle predicts cardiac death in a general population. Eur Heart J. 2003;24:1357-1364.
21. Whang W, Shimbo D, Leviatan E, Newman J, Rautaharju P, Muntner P. Relations between QRST angle, cardiac risk factors, and mortality in the third National Health and Nutrition Examination Survey (NHANES III). Am J Cardiol. 2012;109:981-987.
22. Acar B, Yi G, Hnatkova K, Malik M. Spatial, temporal and wavefront direction characteristics of 12-lead T-wave morphology. Med Biol Eng Comput. 1999;37:574-584.
23. Fridericia LS. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Med Scand. 1920;53:469-486.
24. Williams E. Experimental designs balanced for the estimation of residual effects of treatments. Aust J Chem. 1949;2:149-168.
25. DrugsatFDA. Dofetilide label. 2013. Available at: http://www.accessdata. fda.gov/drugsatfda_docs/label/2013/020931s007lbl.pdf Accessed March 26, 2015.
26. DailyMed. Quinidine sulfate label. 2012. Available at: http://dailymed. nlm.nih.gov/dailymed/drugInfo.cfmsetid=a90a03b0-ffbe-4cf6-90b5-bfb 0412a1cb2. Accessed March 26, 2015.
27. DrugsatFDA. Ranolazine label. 2013. Available at: http://www.accessdata. fda.gov/drugsatfda_docs/label/2013/021526s026lbl.pdf. Accessed March 26, 2015.
28. DailyMed. Verapamil label. 2014. Available at: http://dailymed.nlm.nih. gov/dailymed/drugInfo.cfmsetid=10881745-3a16-44c3-9b94-60433218f1d6. Accessed March 26, 2015.
29. Badilini F, Vaglio M, Sarapa N. Automatic extraction of ECG strips from continuous 12-lead holter recordings for QT analysis at prescheduled versus optimized time points. Ann Noninvasive Electrocardiol. 2009;14: S22-S29.
30. Johannesen L, Vicente J, Galeotti L, Strauss DG. EGClib: library for processing electrocardiograms. Comput Cardiol. 2013;40:951-954.
31. Guldenring D, Finaly D, Strauss D, Galeotti L, Nugent C, Donnelly M, Bond R. Transformation of the Mason-Likar 12-lead electrocardiogram to the Frank vectorcardiogram. Conf Proc IEEE Eng Med Biol Soc. 2012;000:677-680.
32. Draisma HH, Schalij MJ, Wall E, Swenne CA. Elucidation of the spatial ventricular gradient and its link with dispersion of repolarization. Heart Rhythm. 2006;3:1092-1099.
33. Johannesen L, Vicente J, Gray RA, Galeotti L, Loring Z, Garnett CE, Florian JA, Ugander M, Stockbridge N, Strauss DG. Improving the assessment of heart toxicity for all new drugs through translational regulatory science. Clin Pharmacol Ther. 2014;95:501-508.
34. Crumb WJ, Pigott JD, Clarkson CW. Description of a nonselective cation current in human atrium. Circ Res. 1995;77:950-956.
35. Lupoglazoff JM, Denjoy I, Berthet M, Neyroud N, Demay L, Richard P, Hainque B, Vaksmann G, Klug D, Leenhardt A, Maillard G, Coumel P, Guicheney P. Notched T waves on Holter recordings enhance detection of patients with LQT2 (HERG) mutations. Circulation. 2001;103:1095-1101.
36. Sager PT, Gintant G, Turner JR, Pettit S, Stockbridge N. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J. 2014;167:292-300.
37. Couderc JP, Zhou M, Sarapa N, Zareba W. Investigating the effect of sotalol on the repolarization intervals in healthy young individuals. J Electrocardiol. 2008;41:595-602.
38. Zabel M, Acar B, Klingenheben T, Franz MR, Hohnloser SH, Malik M. Analysis of 12-lead T-wave morphology for risk stratification after myocardial infarction. Circulation. 2000;102:1252-1257.
39. Couderc JP, Vaglio M, Xia X, Mcnitt S, Wicker P, Sarapa N, Moss AJ, Zareba W. Impaired T-amplitude adaptation to heart rate characterizes IKr inhibition in the congenital and acquired forms of the long QT syndrome. J Cardiovasc Electrophysiol. 2007;18:1299-1305.
40. Andersen MP, Xue JQ, Graff C, Kanters JK, Toft E, Struijk JJ. New descriptors of T-wave morphology are independent of heart rate. J Electrocardiol. 2008;41:557-561.